Hi Dave, I guess we'd also want to confirm with WP that the study didn't hit any of the Major Adverse Cardiac Events (MACE) Endpoints. As you can see from historical changes at the site, the study has ended some months earlier than estimated.
Cheers,
W
- Forums
- ASX - By Stock
- AVR
- Vascucel
Vascucel, page-12
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$10.00 |
Change
-0.150(1.48%) |
Mkt cap ! $211.3M |
Open | High | Low | Value | Volume |
$10.26 | $10.35 | $9.80 | $295.8K | 29.56K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 22 | $9.87 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$10.00 | 2758 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 22 | 9.870 |
1 | 1000 | 9.860 |
1 | 2000 | 9.850 |
2 | 4587 | 9.800 |
1 | 200 | 9.600 |
Price($) | Vol. | No. |
---|---|---|
10.000 | 2758 | 1 |
10.490 | 198 | 1 |
10.500 | 10000 | 1 |
11.000 | 3000 | 1 |
11.500 | 250 | 1 |
Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online